Study describes success with early use of mpox drug among people with HIV
Study describes success with early use of mpox drug among people with HIV
Today JAMA Internal Medicine published a study demonstrating that people with HIV (PWH) who receive early tecovirimat (Tpoxx) after having mpox symptoms are less likely to experience a full-blow course of illness.
But in an accompanying commentary, experts suggest that, while the findings are encouraging, a blanket recommendation to give Tpoxx to all PWH as soon as mpox is suspected may be premature given the limitations of tecovirimat availability.
The cohort study was based on outcomes seen among PWH diagnosed as having mpox at one of four hospitals in Atlanta, Georgia, from June 1, to October 7, 2022. Fifty-six people were classified as cases and received tecovirimat within 7 days of mpox symptom onset (early tecovirimat group), and 56 were controls who were either treated later or did not receive tecovirimat at all (late or no tecovirimat group).
Thank you for watching the video, wish you health and happiness!
Subscribe to the channel at: https://goo.gl/iz6xA4
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
If you have any questions, please contact us by email: [email protected]
Sincerely thank you!
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Sign up: / @hivaidsprevention
Facebook: / hivaids2024
Twitter: / daubenh
Gmail: [email protected]